Plättchenfunktionshemmer neue pharmakologische Ansätze

K. Schrör

doi:10.1055/s-0038-1660283

Hämostaseologie, Table of Contents

Hamostaseologie 1991; 11(02): 66-75
DOI: 10.1055/s-0038-1660283

Originalarbeiten

Schattauer GmbH

Plättchenfunktionshemmer neue pharmakologische Ansätze

K. Schrör

¹Institut für Pharmakologie der Heinrich-Heine-Universität Düsseldorf

› Author Affiliations

Abstract

Zusammenfassung

Ziel der klinischen Therapie mit Thrombozytenfunktionshemmern ist eine Verhinderung von thrombotischen Gefäßverschlüssen bei bestehendem erhöhten vaskulären Risiko. Aufgrund der Physiologie der Plättchenaktivierung eignen sich hierfür besonders solche Pharmaka, die mit rezeptorgekoppelten zellulären Transduktionsmechanismen interferieren. Azetylsalizylsäure (ASS) als Referenzsubstanz hat den Vorteil einer irreversiblen Hemmung der Plättchensekretion und guter Verträglichkeit bei niedriger Dosierung (<100 mg/d), die offenbar für die Prävention des Herzinfarkts ausreicht. Thromboxansynthesehemmer wirken im Gegensatz zu ASS nicht negativ auf die vaskuläre Prostazyklinsynthese, waren aber in der Klinik bisher ASS nicht überlegen. Thromboxanrezeptorenblocker führen zu einer kombinierten Hemmung von Plättchensekretion und thromboxanmediierten Gefäßspasmen. Neuere oral wirksame Substanzen (GR 32.191; Bay U 3405) scheinen einen Langzeiteffekt zu besitzen. Von erheblichem Interesse sind monoklonale Antikörper gegen den GP-llb/llla-Komplex sowie Hirudin und Ticlopidin.

Full Text

References

LITERATUR
1 Adamus WS, Heuer H, Meade CJ, Frey G, Brecht HM. Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist on ex vivo platelet aggregation. Eur J Clin Pharmacol 1988; 35: 237-40.
2 Adelman B, Gennings C, Strony J, Hanners E. Synergistic inhibition of platelet aggregation by fibrinogen-related peptides. Circ Res 1990; 67: 941-7.
3 Balduini CL, Sinigaglia F, Bertolino G, Bisio A, Noris P, Ascari E. Surface mechanisms of platelet adhesion and aggregation. Heamatologica 1987; 72: 261-8.
4 Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G. Antiplatelet treatment with ticlopidine in unstable angina. Circulation 1990; 82: 17-26.
5 Berglund U, Lassvik C, Wallentin L. Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. Eur Heart J 1987; 08: 25-30.
6 Berglund U, von Schenck H, Wallentin L. Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985; 54: 808-12.
7 Bertele G, Mussoni V, Pintucci G, del Romano C, de Gaetano G, Liobretti A. The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclinanalogue. Thromb Haemost 1989; 61: 286-8.
8 Bjerre JBKnudsen, Kjoller E, Skagen K, Gormsen J. The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. Thromb Haemost 1985; 53: 332-6.
9 Boda Z, Tamas E, Altorjay I, Pfliegler G, Rak K. Congenital deficiency of cyclooxygenase in a woman with generalized atherosclerosis. Scand J Haematol 1981; 07: 65-9.
10 Bruch L. Spasmolytic and antiplatelet effects of the novel TXA₂ antagonist Bay U 3405 in an in vitro model of cerebral arterial spasm. Naunyn-Schmiedeberg’s Arch Pharmacol. 1991 (in press).
11 Braun M, Schrör K. Bay U 3405 inhibits cerebral vasospasm induced by authentic thromboxane A₂ . Stroke 1990; 21 (Suppl IV): 152-4.
12 Briiggener E, Glusa E, Schrör K. Agonistinduced thromboxane formation in platelet rich plasma depends on the anticoagulant. Naunyn-Schmiedeberg’s Arch Pharmacol. 1991 (in press).
13 Bucha E, Nowak G, Markwardt F. Prevention of experimental coronary thrombosis by hirudin. Folia Haematol (Leipzig) 1988; 115: 52-8.
14 Bush LR, Smith III EF. Comparative and combined effects of U-63557A, a TXA₂ synthetase inhibitor, and BM 13.177, a TXA₂ receptor antagonist, on cyclic flow reductions in stenosed canine coronary arteries. Fed Proc. 1987 46. 1316 (abstr).
15 Chester AH, O’Neil GS, Moncada Tadjakarimi S, Yacoub MH. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990; 336: 897-9.
16 Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/ IIIa receptor in an experimental animal model. Blood 1986; 68: 783-6.
17 Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/ IIIa receptor. Circulation 1989; 80: 1766-74.
18 Coller BS, Scudder LE, Berger HJ, luliucci JD. Inhibition of human platelet function in vivo with a monoclonal antibody. With observations on the newly dead as experimental subjects. Ann Int Med 1988; 109: 635-8.
19 Coller BS, Scudder LE. Inhibition of dog platelet function by in vivo infusion of F(ab’)2 fragments of a monoclonal antibody to the glycoprotein Ilb/IIIa receptor. Blood 1985; 66: 1456-9.
20 Darius H, Hossmann V, Schrör K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled doseresponse study. Klin Wochenschr 1986; 64: 545-51.
21 Darius H, Kopp H, Mulfinger A, Spielberger M, Todt M, Schuster CJ, Meyer J. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease. Prostaglandins Clin Res 1989; 301: 417-21.
22 De Clerck F, Beetens J, De Chaffoy de Coucelles, Freyne E, Janssen PAJ. R 68070: Thromboxane A₂ synthetase inhibition and thromboxane A₂/prostaglandin endoperoxide receptor blockade combined in one molecule I. Biochemical profile in vitro. Thromb Haemost 1989; 61: 35-42.
23 De Clerck F, Beetens J, van de Water A, Vercammen E, Janssen PAJ. R 68070: Thromboxane A₂ synthetase inhibition and thromboxane A₂/prostaglandin endoperoxide receptor blockade combined in one molecule II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 1989; 61: 35-42.
24 De Gaetano G, Cerletti C, Dejana E, Yermylen J. Current issues in thrombosis prevention with antiplatelet drugs. Drugs 1986; 31: 517-49.
25 Defreyn G, Bernât A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: A review. Semin Thromb Hemost 1989; 15: 159-66.
26 DeWitt DL, El-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, Smith WL. The aspirinand heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990; 265: 5192-8.
27 Di Minno G, Cerbone AM, Mattioli PL, Iovine C, Mancini M. Functionally thrombasthénie state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-38.
28 Dimaio J, Gibbs B, Munn B, Lefebvre J, Ni F, Konishi Y. Bifunctional thrombin inhibitors based on the sequence of hirudin 45-65. J Biol Chem 1990; 265: 21698-703.
29 Dorn II GW. Cyclic oxidation-reduction reactions regulate thromboxane A₂/prostaglandin H₂ receptor number and affinity in human platelet membranes. J Biol Chem 1990; 265: 4240-6.
30 Dorn II GW, Liel N, Trask JL, Mais DE, Assey ME, Halushka PV. Increased platelet thromboxane A₂/prostaglandin H₂ receptors in patients with acute myocardial infarction. Circulation 1990; 81: 212-8.
31 Feliste R, Delebassee D, Simon MF, Chap H, Defreyn G, Vallee E, Douste-Blazy L, Maffrand JP. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res 1987; 48: 403-15.
32 Fiedler VB, Perzborn E, Seuter F, Rosentreter U, Böshagen H. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(-4fluorophenylsulfonamido)-l ,2,3,4-tetrahydro-9-carbazole-propanoic acid. Arzneimittelforsch 1989; 39: 1527-30.
33 Fischer S, Struppler M, Böhlig B, Bernutz Ch, Wober W, Weber PC. The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man. Circulation 1983; 68: 821-6.
34 FitzGerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-50.
35 FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. New Engl J Med 1984; 310: 1065-8.
36 FitzGerald GA, Oates JA, Hawiger JA, Maas RL, Roberts II LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-88.
37 Fitzpatrick FA, Jones D, Winitz S, Fish HT. Mechanism-based inactivation of thromboxane A₂ synthase. Adv Prostaglandin Thromboxane Leukotriene Res 1990; 21: 161-3.
38 Frishman WH, Christodoulou J, Weksler BB, Smithen C, Killip T, Scheidt S. Aspirin therapy in angina pectoris: effects on platelet aggregation, exercise tolerance, and echocardiographic manifestations of ischemia. Am Heart J 1976; 92: 3-10.
39 Frishman WH, Weksler BB, Christodoulou JP, Smithen C, Killip T. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol. Circulation 1974; 50: 887-96.
40 Fuster V, Stein B, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: An approach based on pathogenesis and risk stratification. Am J Cardiol 1990; 65: 38C-44C.
41 Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 01: 1215-20.
42 Giessen van der WJ, Zijlstra FJ, Berk L, Verdouw PD. The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary thrombosis in the pig. Eur J Pharmacol 1988; 147: 241-8.
43 Gillespie E. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem Pharmacol 1988; 37: 2866-8.
44 Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 1990; 20: 112-8.
45 Green K, Vesterqvist O, Rassmanis G, Edhag O, Henriksson P. Deficient prostacyclin formation after acute myocardial infarction. Lancet 1987; 01: 1037-8.
46 Gresele P, Blockmans D, Deckmyn H, Vermylen J. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and non-responders. J Pharmacol Exp Ther 1988; 246: 301-7.
47 Haft JI. Role of blood platelets in coronary artery disease. Am J Cardiol 1979; 43: 1197-1206.
48 Halushka PV, Mais SE, Saussy Jr DL. Platelet and vascular smooth muscle thromboxane A₂/prostaglandin H₂ receptors. Fed Proc 1987; 46: 149-53.
49 Hanson SR, Pareti FI, Fuggeri ZM, Marzec UM, Kunicki JJ, Montgomery PR, Zimmerman TS, Harker L. Effects of monoclonal antibodies against the platelet glykoprotein Ilb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988; 81: 149-58.
50 Hardisty RM, Powling MJ, Nokes TJC. The action of ticlopidine on human platelets. Thromb Haemost 1990; 64: 150-5.
51 Hass WK, Easton JD, Adams Jr HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989; 321: 501-7.
52 Hawiger J. (ed). Methods in Enzymology. Platelets: Receptors, Adhesion, Secretion. Part A. Vol 169. San Diego: Academic Press; 1989
53 Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-65.
54 Hess H, Mietaschk A, Deichsel G. Druginduced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet 1985; 01: 415-9.
55 Hornby EJ, Foster MR, McCabe PJ, Stratton LE. The inhibitory effect of GR 32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. Thromb Haemost 1989; 61: 429-36.
56 Houston DS, Shepherd JT, Vanhoutte PM. Aggregating human platelets direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries Role of serotonin, thromboxane-A₂ and adenine nucleotides. J Clin Invest 1986; 78: 539-44.
57 Ito T, Ogawa K, Watanabe J, Chen LS, Shikano M, Shibata T, Ito Y, Miyazaki Y, Satake T. Selective thromboxane inhibitor and ischemic heart disease. Biomed Biochim Acta 1984; 43: S125-32.
58 Jackson C, Ball J, Peel J, Lawry J, Greaves M, Preston FE. DN 9693: A phosphodiesterase inhibitor with a platelet membrane effect. Thromb Haemost 1989; 61: 266-9.
59 Jaschonek K, Faul C, Schmidt H, Renn W. Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. Eur J Pharmacol 1988; 147: 187-96.
60 Jaschonek K, Karsch KR, Weisenberger H, Tidow S, Faul C, Renn W. Platelet prostacyclin binding in coronary artery disease. J Am Coll Cardiol 1986; 08: 259-66.
61 Jaschonek K, Muller CP. Platelet and vessel associated prostacyclin and thromboxane A₂/prostaglandin endoperoxide receptors. Eur J Clin Invest 1988; 18: 1-8.
62 Kahn NN, Mueller HS, Sinha AK. Impaired prostaglandin Ei /I ₂ receptor activity of human blood platelets in acute ischemic heart disease. Circ Res 1990; 66: 932-40.
63 Knapp HR, Reilly IAG. In vivo indexes of platelet and vascular function during fishoil administration in patients with atherosclerosis. New Engl J Med 1986; 314: 937-42.
64 Kubisz P, Arabi A, Holan J, Cronberg S. Investigations on platelet function in diabetes mellitus. Haemostasis 1984; 14: 347-53.
65 Lane IF, Lumley P, Michael MF, Peters AM, Mccollum CN. A specific thromboxane receptor blocking drug, AH 23848, reduces platelet deposition on vascular grafts in man. Thromb Haemost 1990; 64: 369-73.
66 Lanza F, Berettz A, Stierle A, Hanau D, Kubina M, Cazenave J-P. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276-88.
67 Lanza F, Beretz A, Stierle A, Corre G, Cazenave JP. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium. Thromb Res 1987; 45: 477-84.
68 Latta G, Schrör K. Kalziumantagonisten und Thrombozytenfunktion. Hämostaseologie 1988; 08: 80-9.
69 Machleidt C, Rose P, Mittmann U. Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RXRA 69. Thromb Res 1985; 37: 595-604.
70 Mac DEIntyre, Bushfield M, MacMillan LJ, Moffat KJ, Murdoch FA, Thomson A, Rossi ÄG, McNicol A. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators. Agents and Actions. 1986. 20 (Suppl, Parnham MJ, Prop G. eds): 45-62.
71 Manson JE, Grobbee DE, Stampfer MJ, Taylor JO, Goldhaber SZ, Gaziano JM, Ridker PM, Buring JE, Hennekens CH. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med 1990; 89: 772-6.
72 Märki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins. Thromb Haemost 1990; 64: 334-8.
73 Markwardt F, Nowak G, Stürzebecher J, Griessbach U, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemostas 1984; 52: 160-3.
74 Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671-8.
75 Mayeux PR, Morton HE, Gillard J, Lord A, Morinelli TA, Boehm A, Mais DE, Halushka PV. The affinities of prostaglandins H2 and thromboxane A2 for their receptors are similar in washed human platelets. Biochem Biophys Res Comm 1988; 157: 733-9.
76 McNicol A, Gerrard JM, Me DEIntyre. Evidence for two mechanisms of thrombin induced platelet activation: one proteolytic, one receptor mediated. Biochem Cell Biol 67: 332-6.
77 Merritt JE, Hallam TJ, Brown AM, Boyfield I, Cooper DG, Hickey DMB, JaxaChamiec AA, Kaumann AJ, Keen M, Kelly E, Kenney CA, Nichols AJ, Smith III EF, Swayne GTG, Mac JDermot, Rink TJ. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br J Pharmacol 1991; 102: 251-9.
78 Mueller HS, Rao PS, Greenberg MA, Buttrick PM, Sussman II, Levite HA, Grose RM, Perez-Davila V, Strain JE, Spaet TH. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. Circulation 1985; 72: 1336-45.
79 Mullane KM, Fornabaio D. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin sensitive pathway. Circ Res 1988; 62: 668-78.
80 Murray R, Shipp E, FitzGerald GA. Prostaglandin endoperoxide Thromboxane A₂ receptor desensitization Cross talk with adenylate cyclase in human platelets. J Biol Chem 1990; 265: 21670-5.
81 Nowak J, FitzGerald GA. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 1989; 03: 380-5.
82 O’Brien JR, Etherington MD, Salmon GP. DN.9693, a phosphodiesterase inhibitor, compared with prostaglandin El and prostacyclin in four platelet “functions” tests. Thromb Res 1988; 50: 237-41.
83 Orlando E, Cortelazzo S, Nosari I, Lepore G, Pagani G, De Gaetano F, Barbui T. Inhibition by ticlopidine of platelet adhesion to human venous subendothelium in patients with diabetes. J Lab Clin Med 1988; 112: 583-8.
84 Patrono C. Aspirin and human platelets: from clinical trials to acétylation of cyclooxygenase and back. Trends Pharmacol Sci 1989; 10: 453-8.
85 Patscheke H. Thromboxane A₂/Prostaglandin H₂ receptor antagonists. A new therapeutic principle. Stroke 1990; 21 (Suppl IV): 139-42.
86 Patscheke H, Staiger C, Neugebauer G, Kaufmann B, Strein K, Endele R, Stegmeier K. The pharmacokinetic and pharmacodynamic profile of the thromboxane A₂-receptor blocker BM 13.177. Clin Pharmacol Ther 1986; 39: 145-50.
87 Perzborn E, Fiedler VB, Seuter F, Stasch JP, Weber H, Sander E, Böshagen H, Rosentreter U. Characterization of Bay U 3405, a novel thromboxane A₂/endoperoxide receptor antagonist. Stroke 1990; 21 (Suppl IV): 143-51.
88 Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricarboxylic acid: A novel inhibitor of the association of von Willebrand factor and platelets. Blood 1988; 72: 1898-903.
89 Plow EF, Marguerie G. Inhibition of fibrinogen binding to human platelets by the tetrapeptide glycyl-L-propyl-L-arginyl-Lproline. Proc Natl Acad Sci (USA) 1982; 79: 3711-5.
90 Rao GH, Escolar G, White JG. Epinephrine reverses the inhibitory influence of aspirin on platelet-vessel wall interaction. Thromb Res 1986; 44: 65-74.
91 Rao GH, White JG, Cox CA. Influence of a calcium-dependent protease inhibitor on platelet activation and secretion. Thromb Res 1987; 47: 625-37.
92 Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo : implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-6.
93 Riess H, Höfling B, v. Arnim T, Hiller E. Thromboxane receptor blockade versus cyclooxygenase inhibition: antiplatelet effects in patients. Thromb Res 1986; 42: 235-45.
94 Risc-Group : Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in man with unstable coronary artery disease. Lancet 1990; 336: 827-30.
95 Ritter JM, Doktor HS, Benjamin N, Barrow SE, Stewart-Long P. On the mechanism of the prolonged action in man of GR 32191, a thromboxane receptor antagonist. Adv Prostaglandin Thromboxane Leukotriene Res 1990; 21: 351-4.
96 Ruggiero M, Lapetina EG. Protease and cyclooxygenase inhibitors synergistically prevent activation of human platelets. Proc Natl Acad Sci (USA) 1986; 83: 3456-9.
97 Schillinger E. New results in the development of prostaglandin analogues. New Trends Lipid Med Res 1989; 03: 94-9.
98 Schrör K. Thromboxane A₂ and platelets as mediators of coronary arterial vasoconstriction in myocardial ischaemia. Eur Heart J 1990; 11 (Suppl B): 27-34.
99 Schrör K, Braun M. Platelets as a source of vasoactive mediators. Stroke 1990; 21 (Suppl IV): 32-5.
100 Schrör K, Hohlfeld Th. Koagulation, Thrombose und Fibrinolyse bei myokardialer Ischämie. In: Heusch G. (Hrsg). Pathophysiologie und rationale Pharmakotherapie der Myokardischämie. Darmstadt: Steinkopff; 1990: 89-117.
101 Schrör K, Löbel P, Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type Ha hypercholesterolemia. Eicosanoids 1989; 02: 39-46.
102 Schumacher WA, Heran CL, Goldenberg HJ, Harris DN, Ogletree ML. Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys. Am J Physiol 1989; 256: H726-34.
103 Seiler BM, Arnold AJ, Stanton HC. Inhibitors of inositole trisphosphate-induced CA⁺⁺ release from isolated platelet membrane vesicles. Biochem Pharmacol 1987; 36: 3331-7.
104 Seiler S, Brassard CL, Arnold AJ, Meanwell NA, Fleming JS, Keely SL. Octimibate inhibition of platelet aggregation Stimulation of adenylate cyclase through prostacyclin receptor activation. J Pharmacol Exp Ther 1990; 255: 1021-6.
105 Shebuski RJ, Berry DE, Bennett DB, Romoff T, Storer BL, Ali F, Samamen J. Demonstration of ac-arg-gly-asp-ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration. Thromb Haemost 1989; 61: 183-9.
106 Shikano M, Ito T, Ogawa K, Satake T. Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise. Jap Heart J 1987; 28: 663-7.
107 Siess W. Molecular mechanism of platelet activation. Physiol Rev 1989; 69: 58-178.
108 Sills T, Cowley AJ, Heptinstall S. Aspirin and dazoxiben as inhibitors of platelet behaviour: modification fo their effects by agents that alter cAMP production. Thromb Res 1986; 42: 91-8.
109 Sills T, Heptinstall S. Effects of a thromboxane synthase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour. Thromb Haemost 1986; 55: 305-8.
110 Simpson AW, Reeves ML, Rink TJ. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem Pharmacol 1988; 37: 2315-20.
111 Sinzinger H, Silberbauer K, Horsch AK, Gall A. Decreased sensitivity of human platelets to PGI₂ during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease a rebound phenomenon?. Prostaglandins 1981; 21: 49-51.
112 Spacey GD, Bonser RW, Randall RW, Garland LG. Selectivity of protein kinase inhibitors in human intact platelets. Cell Signalling 1990; 02: 329-38.
113 Strony JT, Folts JD, Adelman B. (1989). In vivo antiplatelet effect of gly-arg-gly-aspser in the stenosed canine coronary artery occlusion model. Clin Res. 1989 54. 117A. (abstr).
114 Strony JT, Phillips M, Brands D, Moake J, Adelman B. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation 1990; 81: 1106-14.
115 Stürzebecher S, Hildebrand M, Schöbel C, Sefert W, Staks T. Platelet inhibitory and haemodynamic effects of a new stable PGI₂ analogue, cicaprost (ZK 96480), in different animal species and in man. Biomed Biochim Acta 1988; 47: S45-7.
116 Sunkel CE, Fau Mde Casa-Juana, Cillero FJ, Priego JG, Ortega MP. Synthesis, platelet aggregation inhibitory activity and in vivo antithrombotic activity of new 1,4dihydropyridines. J Med Chem 1988; 31: 1886-90.
117 Takahara K, Murray R, FitzGerald GA, FitzGerald DJ. The response to thromboxane A₂ analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 1990; 265: 6836-44.
118 Thiemermann C, Ney P, Schrör K. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis. Eur J Pharmacol 1988; 155: 57-67.
119 Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori M, Sirtori GR. Increased platelet sensitivity and thromboxane B₂ formation in type II hyperlipoproteinaemic patients. Eur J Clin Invest 1984; 14: 329-33.
120 Tyler HM, Saxton CAPD, Parry MJ. Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet 1981; 01: 629-32.
121 Uchiyama S, Sone R, Nagayama T, Shibagaki Y, Koayashi I, Maruyama S, Kusakabe K. Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia. Stroke 1989; 20: 1643-7.
122 Verheggen R, Schrör K. The modification of platelet-induced vasoconstriction by a thromboxane receptor antagonist. J Cardio vase Pharmacol 1986; 08: 483-90.
123 Williams SB, McKeown LP, Gralnick HR. Asialo-von Willebrand factor binding to and aggregation of platelets: Effects of inhibitors of platelet metabolism and function. J Lab Clin Med 1987; 109: 560-65.
124 Woods AI, Lazzari MA. Aspirin effect on the relase of plasminogen activator inhibitor by human platelets. Thromb Res 1988; 52: 119-25.